Literature DB >> 31262874

Phenformin Induces Caspase-dependent Apoptosis of FaDu Head and Neck Squamous Cell Carcinoma Cells.

Yo-Seob Seo1, Tae-Hyeon Kim2, Hyangi Lim2, Ji-Su Oh3, Jae-Seek You3, Gyeong-Je Lee4, Sun-Kyoung Yu2, DO Kyung Kim2, Heung-Joong Kim2, Chun Sung Kim2, Sook-Young Lee5, Su-Gwan Kim3, Jae-Sung Kim6.   

Abstract

BACKGROUND/AIM: The present study aimed to investigate the apoptotic effects of phenformin, a therapeutic agent for diabetes, on head and neck squamous cell carcinoma (HNSCC).
MATERIALS AND METHODS: Cytotoxicity was measured by the MTT and live/dead cell assay. Phenformin-induced apoptotic FaDu cell death and its associated cellular signaling pathways were investigated by hematoxylin and eosin staining, 4',6-diamidino-2-phenylindole staining, caspase-3 activity assay, fluorescence-activated cell sorting analysis, and western blotting.
RESULTS: Phenformin promoted death of and apoptotic processes in FaDu cells, including morphological alterations and nuclear condensation. Furthermore, treatment with phenformin increased caspase-3 activity and apoptotic populations via the caspase cascade through cleavage of capspase-8, -9, and -3 and poly(ADP-ribose) polymerase in FaDu cells. Moreover, phosphorylation levels of mitogen-activated protein kinases, nuclear factor-κB, and AKT were down-regulated in FaDu cells by phenformin.
CONCLUSION: Phenformin induced death of FaDu cells via caspase-dependent extrinsic and intrinsic apoptosis pathways and is a promising novel therapeutic agent for HNSCC. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Phenformin; apoptosis; caspase; head and neck squamous carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31262874     DOI: 10.21873/anticanres.13496

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.

Authors:  Varun Monga; Benjamin J Miller; Munir Tanas; Sarag Boukhar; Bryan Allen; Carryn Anderson; Laura Stephens; Stacey Hartwig; Steven Varga; Jon Houtman; Lei Wang; Weizhou Zhang; Omar Jaber; Jon Thomason; David Kuehn; Maheen Rajput; Catherine Metz; K D Zamba; Sarah Mott; Chinemerem Abanonu; Sudershan Bhatia; Mohammed Milhem
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.